Q2 EPS Estimates for Pyxis Oncology Lifted by HC Wainwright

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for shares of Pyxis Oncology in a research note issued to investors on Monday, July 6th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.29) for the quarter, up from their prior forecast of ($0.38). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q3 2026 earnings at ($0.27) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.10) EPS, Q1 2027 earnings at ($0.27) EPS, Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.22) EPS, Q4 2027 earnings at ($0.23) EPS, FY2027 earnings at ($0.88) EPS, FY2028 earnings at ($0.44) EPS, FY2029 earnings at $0.20 EPS and FY2030 earnings at $0.77 EPS.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02).

PYXS has been the subject of several other research reports. Wall Street Zen cut shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Leerink Partners decreased their target price on Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating for the company in a report on Thursday, July 2nd. Wedbush started coverage on Pyxis Oncology in a research note on Tuesday, May 5th. They set an “outperform” rating and a $6.00 target price for the company. Weiss Ratings downgraded Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Finally, Stifel Nicolaus decreased their price objective on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, March 24th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Pyxis Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $6.86.

Pyxis Oncology Stock Performance

Shares of PYXS stock opened at $3.07 on Wednesday. The stock has a market capitalization of $194.48 million, a P/E ratio of -2.34 and a beta of 1.30. Pyxis Oncology has a fifty-two week low of $0.97 and a fifty-two week high of $5.55. The company has a 50 day moving average price of $2.09 and a 200 day moving average price of $1.71.

Institutional Trading of Pyxis Oncology

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Maia Wealth LLC purchased a new stake in Pyxis Oncology during the 4th quarter worth about $25,000. Engineers Gate Manager LP purchased a new position in shares of Pyxis Oncology in the 4th quarter valued at about $26,000. Fox Run Management L.L.C. acquired a new stake in shares of Pyxis Oncology during the 4th quarter worth about $26,000. Avanza Fonder AB acquired a new stake in shares of Pyxis Oncology during the 4th quarter worth about $31,000. Finally, XTX Topco Ltd purchased a new stake in Pyxis Oncology during the second quarter worth approximately $40,000. 39.07% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Pyxis Oncology

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Pyxis Oncology and reiterated a $7.00 price target, signaling continued upside potential despite recent estimate cuts.
• Neutral Sentiment: The analyst updated multiple longer-term forecasts, including improving its FY2030 EPS estimate to $0.77 from $0.99 previously, while still modeling the company as profitable later in the decade.
• Negative Sentiment: HC Wainwright lowered earnings expectations for several near- and medium-term periods, including FY2026 to ($1.10), FY2027 to ($0.88), and quarterly estimates for Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027, and Q4 2027, which points to a longer path to profitability. Article Title

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.